Novo Nordisk, seen as lagging in obesity drug race, says it’s playing the long game

Taking stock of the drug industry, from the lab to the medicine chest

June 25, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Re-sending today's email with fresh news! Apologies for an earlier production error.

Adobe STAT+ | Novo Nordisk, seen as lagging in obesity drug race, says it's playing the long game Executives argue coming readouts on next-generation candidates such as CagriSema and amycretin and overall strategy will pay off. By Elaine Chen CDC vaccine advisory committee to review long-approved immunizations The decision by the new ACIP, which was reconstituted by HHS Secretary Robert F. Kennedy Jr., reflects 'anti-vaccine talking points,' advocate says. By Jason Mast STAT+ | NIH halts grant terminations 'effective immediately,' email says Hours after federal judge rules against Trump administration on previously cancelled grants, NIH orders stop to all pending terminations By Anil Oza

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser